HealthPharma & Biotech
Polynovo Ltd

Polynovo follows swift re-rating with a capital raising

The halt will remain in place until Tuesday 25th September 2017.

The company's shares are in pre-open

Polynovo Ltd's (ASX:PNV) shares last traded at $0.285, or around 60% higher than a month ago, with the company receiving a positive re-rating following its first U.S. sales of NovoSorb BTM™

NovoSorb is a tissue scaffold that facilitates the regeneration of the dermis when it has been lost or damaged through trauma, burns, surgery or wounding.

Polynovo is now heading to market with a capital raising, and the ASX has granted a trading halt to prepare.

The halt will remain in place until the opening of trade on Tuesday 25th September 2017, or earlier if an announcement is made to the market.

Quick facts: Polynovo Ltd

Price: $2.24

Market: ASX
Market Cap: $1.48 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Northern Minerals reveals talks with US government agencies,...

Northern Minerals Ltd (ASX:NTU) CEO George Bauk tells Proactive he recently met US government agencies, who he says wanted to get a better sense of the Australian company's progress with its dysprosium production, and its strategy going forward. Bauk is currently in New York meeting with...

16 hours, 6 minutes ago

2 min read